TRIAL DETAIL

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Drug:
Trial Name:
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
NCT#:
Conditions:
Solid Tumors
Status:
Recruiting
Phase:
2
Start Date 08/26/2019
Age of Trial (yrs) 2.2
Treatment Phase:
Gleevec-resistant
Drug Category:
SDH-directed
Strategy:
Block related tumor signal paths
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
NCI-2019-01365 NCI-2019-01365 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) NCI10220 10220 ( Other Identifier: University of Texas MD Anderson Cancer Center LAO ) 10220 ( Other Identifier: CTEP ) UM1CA186688 ( U.S. NIH Grant/Contract )
Sponsor:
National Cancer Institute (NCI)
Patient Contact:
Principal Investigator: Vivek Subbiah University of Texas MD Anderson Cancer Center LAO
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
Patients must have histologically confirmed malignancy that is metastatic or unresectable

Patient must have histopathologic confirmation of advanced solid tumor with NF1 mutation, NF1 mutant MPNST, KEAP1/NRF2 mutant and STK11/LKB1 mutant tumors (molecular profiling performed in any Clinical Laboratory Improvement Act [CLIA] certified lab [including tumor and circulating cell-free (cf)DNA], e.g. Caris, FoundationOne, FoundationAct, Oncomine, Guardant etc.)

NOTE: For all cohorts annotation for actionability will be performed by the PRECISION ONCOLOGY DECISION SUPPORT (PODS) TEAM SHEIKH KHALIFA BIN ZAYED AL NAHYAN INSTITUTE FOR PERSONALIZED CANCER THERAPY (IPCT) THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 6565 MD ANDERSON BLVD, HOUSTON, TX 77030

Patient must have no standard therapies available
Patients for NF1 mutant MPNST and NF1 mutant non-MPNST cohorts must be >= 40 kg

Trial Links

Trial Results

Drug Information

Calithera Prgrams CB-839
 
2014 AACR Poster
 

Trial Sites

Name
Address
City
State
Zip
Country
12902 Magnolia Dr.
Tampa
FL
33612
USA
9000 Rockville Pike
Bethesda
MD
20892
USA
450 Brookline Ave
Boston
MA
02215-5450
USA
New York
NY
10032
USA
Columbus
OH
43210
USA
Pittsburgh
PA
15232
USA
1505 Holcombe Blvd.
Houston
TX
77030
USA
Tampa
FL
33607
USA
Lexington
KY
40536
USA